ABSTRACT
Objective Machine-learning (ML) algorithms allow for improved prediction of sepsis syndromes in the ED using data from electronic medical records. Transfer learning, a new subfield of ML, allows for generalizability of an algorithm across clinical sites. We aimed to validate the Artificial Intelligence Sepsis Expert (AISE) for the prediction of delayed septic shock in a cohort of patients treated in the ED and demonstrate the feasibility of transfer learning to improve external validity at a second site.
Methods Observational cohort study utilizing data from over 180,000 patients from two academic medical centers between 2014 and 2019 using multiple definitions of sepsis. The AISE algorithm was trained using 40 input variables at the development site to predict delayed septic shock (occurring greater than 4 hours after ED triage) at varying prediction windows. We then validated the AISE algorithm at a second site using transfer learning to demonstrate generalizability of the algorithm.
Results We identified 9354 patients with severe sepsis of which 723 developed septic shock at least 4 hours after triage. The AISE algorithm demonstrated excellent area under the receiver operating curve (>0.8) at 8 and 12 hours for the prediction of delayed septic shock. Transfer learning significantly improved the test characteristics of the AISE algorithm and yielded comparable performance at the validation site.
Conclusions The AISE algorithm accurately predicted the development of delayed septic shock. The use of transfer learning allowed for significantly improved external validity and generalizability at a second site. Future prospective studies are indicated to evaluate the clinical utility of this model.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Wardi is supported by the National Foundation of Emergency Medicine and funding from the Gordon and Betty Moore Foundation (#GBMF9052). He has received speaker's fees from Thermo-Fisher and consulting fees from General Electric. Dr. Holder is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (#UL1TR002378 and #KL2TR002381). Dr. Nemati is funded by the National Institutes of Health (#K01ES025445), National Science Foundation (#1822378) Biomedical Advanced Research and Development Authority (#HHSO100201900015C), and the Gordon and Betty Moore Foundation (#GBMF9052). Dr. Carlile, Dr. Shashikumar and Dr. Hayden have no conflicts of interest to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board approval of the study was obtained at both sites with a waiver of informed consent (Emory #110675 and UC San Diego #191098)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dr. Wardi is supported by the National Foundation of Emergency Medicine and funding from the Gordon and Betty Moore Foundation (#GBMF9052). He has received speaker’s fees from Thermo-Fisher and consulting fees from General Electric. Dr. Holder is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (#UL1TR002378 and #KL2TR002381). Dr. Nemati is funded by the National Institutes of Health (#K01ES025445), National Science Foundation (#1822378) Biomedical Advanced Research and Development Authority (#HHSO100201900015C), and the Gordon and Betty Moore Foundation (#GBMF9052). Dr. Carlile, Dr. Shashikumar and Dr. Hayden have no conflicts of interest to report.
Data Availability
Access to the computer code used in this research is available upon request to the corresponding author.
